SAN FRANCISCO (GenomeWeb) – MicroGen Dx is developing PCR and next-generation sequencing tests to diagnose microbial infections, with its initial focus on urological and prosthetic joint infections.
The company, which is headquartered in Orlando, Florida and has a CLIA-certified, CAP-accredited laboratory in Lubbock, Texas, changed its name from Pathogenius after current CEO Rick Martin purchased it last year.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
